We found that curcumol treatment decreased the binding ability of EZH2 to the promoter of downstream effectors (EphB3, p21, and CDKN1B) and the H3K27me3 modification in the promoter regions of effectors and increased the expression levels of effectors in glioma. The gene discussed is CDKN1B; the disease is glioma.